Nutrileads announces positive outcome proof of concept study in humans

November 24th, 2016, Wageningen, The Netherlands.

NUTRILEADS B.V., a Dutch Nutrition & Health startup today announces the positive outcome of a proof of concept study in humans demonstrating that its lead ingredient IMPP-1 is safe, well tolerated and supports immune function in humans.

NUTRILEADS develops nutritional ingredients for application in health-promoting food products. The company was founded in 2012 based upon an invention originating from Unilever. In 2015, NutriLeads closed a successful seed financing round with an investor syndicate comprising Thuja Capital, DSM Venturing BV, PPM Oost and Shift Invest and is currently discussing aseries A financing.

NutriLeads’ lead ingredient Immuno Modulatory Plant Polysaccharide-1 (IMPP-1) can be sustainably sourced from food crops. Nutrileads is developing this patented ingredient for different food applications including dietary supplements, medical food and functional food to reach various target populations.

The results of the first proof of concept study with IMPP-1 in healthy volunteers were evaluated by an international group of key opinion leaders from industry and academia. The experts concluded that the results demonstrate excellent tolerability and safety characteristics and significant and dose dependent stimulation of the immune system.

The positive result in first proof of concept study in healthy volunteers provides the necessary confidence to go full speed ahead with our ambitious development program including several clinical trials to support the use of this proprietary ingredient from sustainable sources as dietary supplement and for application in specialized functional and medical food products” indicates Ruud Albers, PhD, CEO of NutriLeads.

Share

Nutrileads wins prestigious eurostars grant

November 21st, 2016, Wageningen, The Netherlands.

NUTRILEADS B.V., a Dutch Nutrition & Health startup has won a prestigious Eurostars grant to support the development of its lead ingredient IMPP-1 for application in medical foods.

Nutrileads (as consortium leader) and 4 partners from the Netherlands, Germany and Finland have been awarded a € 2 million Eurostars project called NIMF. The consortium will develop Nutrileads’ proprietary ingredient Immune Modulatory Plant Polysaccharide-1 (IMPP-1) into a new ingredient for medical food products to fight impaired immune functioning as a result of malnutrition (particularly common in a variety of patient groups). Nutrileads is developing this ingredient, in addition to medical food products, also for other food applications like dietary supplements and functional food.

The NIMF project was the highest rated project with a Dutch participant, ranking 4th of 269 applications across all fields in Europe. Erik Dam, CBO of NutriLeads emphasizes: “The very positive evaluation of the NIMF project provides a further validation of the relevance of our proposition and the quality of our science, team and partners”.

Share

NutriLeads receives an ‘innovatie voucher’ of the European Regional Development Fund to support a Proof of Concept trial in human volunteers

June 13th, 2016. Brief summary of the supported project’ PoC trial’ (PROJ-00535): Nutrileads BV identifies and develops innovative food ingredients that have a positive health effect. Its lead ingredient IMPP-1 supports immune function and increases resistance to common infections. In this project, IMPP-1 obtained from a food crop is tested in a proof of concept study in human volunteers to determine tolerability and effectiveness. This is an important step in the further development of IMPP-1 as health promoting ingredient for application in dietary supplements, medical and functional foods

Share

NutriLeads announces collaboration with DSM Nutritional Products

May 26th, 2016, Wageningen, The Netherlands

Dutch nutritional health ingredients startup NutriLeads B.V. announces the signing of a collaboration agreement with DSM Nutritional Products for the further development of its lead ingredient.

Following the successful closure of a seed investment in October 2015, NutriLeads announces that it has initiated a collaboration with DSM Nutritional Products to speed up development and to scale up production of its leading ingredient, a proprietary novel polysaccharide to support immune function and increase resistance to infections. Immune support and resistance to infections and colds is a major health concern of consumers and patients alike and is the main category of supplements used by consumers of all ages.

Dr Ruud Albers, CEO of Nutrileads: “I am very pleased that we embark on this co-development with DSM Nutritional Products, a strong partner committed to innovation. The experience and scale of DSM Nutritional Products will help to bring the benefits of our proprietary ingredient faster to consumers and patients”.

Dr Rob Beudeker, VP Innovation Human Nutrition and Health at DSM: “We welcome this collaboration with NutriLeads. They own some interesting technology and we would like to help them bringing this to commercial fruition. Immunity benefits are very relevant for families all over the world.

Share

NutriLeads closes seed financing round

November 18th, 2015, Wageningen, The Netherlands

Dutch nutritional health ingredients startup NUTRILEADS B.V. today announces the successful closure of a seed financing round with an investment syndicate comprising DSM VENTURING, PPM OOST, SHIFT INVEST and THUJA CAPITAL.

NUTRILEADS develops nutritional ingredients for application in health-promoting food products. The company was founded in December 2011 based on an invention initially made at Unilever. In 2013, NutriLeads, together with NIZO Food Research, obtained a grant from the top-sector Agri & Food to start the preclinical development of its lead in gredient.

This seed investment enables us to accelerate development and to move our lead ingredient to clinical testing. This is a major step in achieving our ambition to partner with ingredient suppliers and food companies to bring the benefits of our health ingredients to patients and consumers” indicates Ruud Albers, PhD, former Nutrition and Health R&D director at Unilever and CEO of NutriLeads.

NutriLeads’ lead ingredient is derived from a traditional herbal remedy, which was shown in clinical trials to support immune function and to improve resistance to infections. It was discovered that the active component can be sustain ably sourced from food crops. NutriLeads develops this proprietary ingredient as dietary supplement and for application in specialized functional and medical food products.

Erik Dam, former VP at Danone Advanced Medical Nutrition and CBO of NutriLeads emphasizes: “The consortium of investors is carefully composed to support NutriLeads through its next development stages and it provides highly relevant and complementary expertise and networks”.

Michel Briejer, PhD, from THUJA CAPITAL, lead investor of the syndicate, indicates that “NutriLeads combines experienced management and deep knowledge with interesting assets initially identified at Unilever. We have recognized this as an exciting opportunity to create value for both patients/consumers as well as investors“.

Marius Prins, CEO of PPM Oost, who is also very pleased with the investment in NutriLeads, states: “Significant value creation by bringing the benefits of health ingredients to patients and consumers is highly relevant to our fund Innovatie-en Energiefonds Gelderland (IEG). In addition, this strategic investment further strengthens the ecosystem of Wageningen UR and the Campus Development”.

Share

NutriLeads presents at Foodvalley expo 2015

October 12th, 2015

Ruud Albers, CEO of NutriLeads, will give a presentation at the Science2Business event at the Foodvalley expo 2015 in Wageningen on Monday October 12th 2015. The presentation titled ‘IMPP-1, a plant fiber that modulates immune function’ will be held in session 2: GI functioning in animal and human health.

Share

Erik Dam joins the management team of NutriLeads

August 31st, 2015

NutriLeads announces that Erik Dam will join its management team as Chief Business Officer. With his experience in pharma and (medical) foods including VP roles at Baxter and Danone, Erik brings critical experience in strategy, marketing, sales, finance and general management to the company. Ruud Albers, former R&D director at Unilever and CEO of NutriLeads, indicates “over the past months we found our expertise, networks and personalities to be complementary. I am honored by his confidence in the company and I am very pleased to welcome Erik on board of NutriLeads. With his experience NutriLeads is well positioned for the next phase of its development”.

Read Erik’s profile

Share